{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:59:07Z","timestamp":1793804347391,"version":"4.6.1"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T00:00:00Z","timestamp":1683936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["946222"],"award-info":[{"award-number":["946222"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ajpc.2023.100502","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T21:26:14Z","timestamp":1684963574000},"page":"100502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":127,"special_numbering":"C","title":["Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5547-5084","authenticated-orcid":false,"given":"Erin D.","family":"Michos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena W.","family":"Rodbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ajpc.2023.100502_bib0001","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.2337\/dc16-0614","article-title":"Risk of cause-specific death in individuals with diabetes: a competing risks analysis","volume":"39","author":"Baena-Diez","year":"2016","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.ajpc.2023.100502_bib0002","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archinte.167.11.1145","article-title":"Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease","volume":"167","author":"Franco","year":"2007","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.ajpc.2023.100502_bib0003","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jama.2015.7008","article-title":"Association of cardiometabolic multimorbidity with mortality","volume":"314","author":"Di Angelantonio","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ajpc.2023.100502_bib0004","series-title":"2018 USRDS annual data report: epidemiology of kidney disease in the United States","year":"2018"},{"issue":"11","key":"10.1016\/j.ajpc.2023.100502_bib0005","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ajpc.2023.100502_bib0006","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.ajpc.2023.100502_bib0007","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO)","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.ajpc.2023.100502_bib0008","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes","volume":"20","author":"Ninomiya","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"9854","key":"10.1016\/j.ajpc.2023.100502_bib0009","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ajpc.2023.100502_bib0010","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.2337\/dc20-2715","article-title":"Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. Health Care Organizations","volume":"44","author":"Stempniewicz","year":"2021","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.ajpc.2023.100502_bib0011","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ajpc.2023.100502_bib0012","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajpc.2023.100502_bib0013","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1524-6175.2002.00749.x","article-title":"Type 2 diabetes: RENAAL and IDNT\u2013the emergence of new treatment options","volume":"4","author":"Sica","year":"2002","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"2","key":"10.1016\/j.ajpc.2023.100502_bib0014","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"24","key":"10.1016\/j.ajpc.2023.100502_bib0015","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ajpc.2023.100502_bib0016","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajpc.2023.100502_bib0017","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2023.100502_bib0018","article-title":"Effects of SGLT2 inhibitors on renal outcomes in patients with chronic kidney disease: a meta-analysis","volume":"8","author":"Li","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"10.1016\/j.ajpc.2023.100502_bib0019","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/ejhf.2135","article-title":"Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk","volume":"23","author":"Bhatia","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.ajpc.2023.100502_bib0020","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.kint.2022.06.013","article-title":"Executive summary of the KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease: an update based on rapidly emerging new evidence","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int"},{"issue":"5S","key":"10.1016\/j.ajpc.2023.100502_bib0021","first-page":"S1","article-title":"Kidney disease: improving global outcomes diabetes work G. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"issue":"23","key":"10.1016\/j.ajpc.2023.100502_bib0022","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ajpc.2023.100502_bib0023","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ajpc.2023.100502_bib0024","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.ajpc.2023.100502_bib0025","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.ajpc.2023.100502_bib0026","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.ajpc.2023.100502_bib0027","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-019-0942-x","article-title":"Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial","volume":"18","author":"Clegg","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.ajpc.2023.100502_bib0028","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/dom.13978","article-title":"Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: lIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial","volume":"22","author":"Blonde","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ajpc.2023.100502_bib0029","unstructured":"A research study to see how semaglutide works compared to placebo in people with type 2 diabetes and chronic kidney disease (FLOW). ClinicalTrials.gov identifier: NCT03819153. ClinicalTrials.gov 2021 December 7, 2021 September 15, 2021]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03819153."},{"issue":"4","key":"10.1016\/j.ajpc.2023.100502_bib0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1016\/j.ajpc.2023.100502_bib0031","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/medicina55060233","article-title":"GLP-1 receptor agonists and kidney protection","volume":"55","author":"Greco","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"10","key":"10.1016\/j.ajpc.2023.100502_bib0032","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/dom.12982","article-title":"Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor","volume":"19","author":"DeFronzo","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.ajpc.2023.100502_bib0033","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1016\/j.ajpc.2023.100502_bib0034","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0735-1097(21)02964-8","article-title":"Semaglutide resduces high-sensitivity CRP levels across different treatment formulations: exploratory analysis of SUSTAIN 3 and PIONEER 1, 2, and 5 trials","volume":"77","author":"Rosenstock","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ajpc.2023.100502_bib0035","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.ajpc.2023.100502_bib0036","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6518221","article-title":"The effects of glucagon-like peptide-1 receptor agonists and dipeptydilpeptidase-4 inhibitors on blood pressure and cardiovascular complications in diabetes","volume":"2021","author":"Yaribeygi","year":"2021","journal-title":"J Diabetes Res"},{"issue":"4","key":"10.1016\/j.ajpc.2023.100502_bib0037","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ajpc.2023.100502_bib0038","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10157","key":"10.1016\/j.ajpc.2023.100502_bib0039","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"10193","key":"10.1016\/j.ajpc.2023.100502_bib0040","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ajpc.2023.100502_bib0041","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ajpc.2023.100502_bib0042","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ajpc.2023.100502_bib0043","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ajpc.2023.100502_bib0044","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ajpc.2023.100502_bib0045","first-page":"S125","article-title":"Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ajpc.2023.100502_bib0046","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology solution set oversight committee","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ajpc.2023.100502_bib0047","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.ajpc.2023.100502_bib0048","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.2215\/CJN.18771220","article-title":"GLP-1 receptor agonists in diabetic kidney disease","volume":"16","author":"Michos","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ajpc.2023.100502_bib0049","unstructured":"A heart disease study of semaglutide in patients with type 2 diabetes (SOUL). ClinicalTrials.gov identifier: NCT03914326. 2021 December 10, 2021 January 18, 2022]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03914326."},{"issue":"1","key":"10.1016\/j.ajpc.2023.100502_bib0050","first-page":"i205","article-title":"eGFR loss with glucagon-like peptide-1 (GLP-1) analogue treatment: data from SUSTAIN 6 and LEADER","volume":"34","author":"Perkovic","year":"2019","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1016\/j.ajpc.2023.100502_bib0051","first-page":"i205","article-title":"Effects of semaglutide and liraglutide on urinary albumin-to-creatinine ratio (UACR) - a pooled analysis of SUSTAIN 6 and LEADER","volume":"34","author":"Perkovic","year":"2019","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1016\/j.ajpc.2023.100502_bib0052","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.ajpc.2023.100502_bib0053","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2337\/dc20-1622","article-title":"Changes in albuminuria predict cardiovascular and renal outcomes in type 2 diabetes: a post Hoc analysis of the LEADER trial","volume":"44","author":"Persson","year":"2021","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.ajpc.2023.100502_bib0054","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ajpc.2023.100502_bib0055","doi-asserted-by":"crossref","first-page":"254","DOI":"10.34067\/KID.0005852020","article-title":"Clinical outcomes by albuminuria status with dulaglutide versus insulin glargine in participants with diabetes and CKD: AWARD-7 exploratory analysis","volume":"360","author":"Tuttle","year":"2021","journal-title":"Kidney"},{"issue":"1","key":"10.1016\/j.ajpc.2023.100502_bib0056","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ajpc.2023.100502_bib0057","doi-asserted-by":"crossref","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: an updated review of head-to-head clinical studies","volume":"12","author":"Trujillo","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ajpc.2023.100502_bib0058","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13300-018-0535-9","article-title":"A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes","volume":"10","author":"Romera","year":"2019","journal-title":"Diabetes Ther"},{"issue":"1","key":"10.1016\/j.ajpc.2023.100502_bib0059","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-016-0490-6","article-title":"Differential effects of glucagon-like peptide-1 receptor agonists on heart rate","volume":"16","author":"Lorenz","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.ajpc.2023.100502_bib0060","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.18549\/PharmPract.2019.4.1588","article-title":"Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series","volume":"17","author":"Lajthia","year":"2019","journal-title":"Pharm Pract (Granada)"},{"issue":"7","key":"10.1016\/j.ajpc.2023.100502_bib0061","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.ajpc.2023.100502_bib0062","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.ajpc.2023.100502_bib0063","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/FJC.0000000000000864","article-title":"Antihyperglycemic therapies with expansions of US Food and Drug Administration indications to reduce cardiovascular events: prescribing patterns within an academic medical center","volume":"76","author":"Hamid","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"issue":"7","key":"10.1016\/j.ajpc.2023.100502_bib0064","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/CIRCULATIONAHA.119.041730","article-title":"Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease","volume":"140","author":"Arnold","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ajpc.2023.100502_bib0065","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/XCE.0000000000000195","article-title":"Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications","volume":"9","author":"Gunawan","year":"2020","journal-title":"Cardiovasc Endocrinol Metab"},{"issue":"16","key":"10.1016\/j.ajpc.2023.100502_bib0066","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2023.100502_bib0067","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2020.07.008","article-title":"Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design","volume":"229","author":"Ryan","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.ajpc.2023.100502_bib0068","unstructured":"Semaglutide effects on heart disease and stroke in patients with overweight or obesity (SELECT). ClinicalTrials.gov identifier: NCT03574597. 2021 November 30, 2021 January 18, 2022]; Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03574597."},{"issue":"10295","key":"10.1016\/j.ajpc.2023.100502_bib0069","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ajpc.2023.100502_bib0070","unstructured":"A study of tirzepatide (LY3298176) compared with dulaglutide on major cardiovascular events in participants with type 2 diabetes (SURPASS-CVOT). ClinicalTrials.gov identifier: NCT04255433. 2022 January 6, 2022 January 18, 2022]; Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04255433."},{"key":"10.1016\/j.ajpc.2023.100502_bib0071","unstructured":"A study of tirzepatide (LY3298176) in participants with overweight or obesity and chronic kidney disease with or without type 2 diabetes (TREASURE-CKD). ClinicalTrial.gov identifier: NCT05536804. 2023 March 27, 2023 [cited 2023 March 28, 2023]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05536804."},{"key":"10.1016\/j.ajpc.2023.100502_bib0072","unstructured":"A research study to find out how semaglutide works in the kidneys compared to placebo, in people with type 2 diabetes and chronic kidney disease (REMODEL). ClinicalTrials.gov identifier: NCT04865770. ClinicalTrials.gov 2021 December 15, 2021 August 25, 2021]; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04865770."}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667723000430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667723000430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:38:06Z","timestamp":1763005086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667723000430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":72,"alternative-id":["S2666667723000430"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2023.100502","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2023.100502","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100502"}}